StreetInsider.com News Articles

Form 8-K Entrada Therapeutics, For: Oct 14

Wed, 14 Oct 2026 07:52:00 -0400

si-local-file:///var/storage/secattach/20261014/27183807.html

Entrada Therapeutics clears DMC review, advances DMD study to top dose

Wed, 14 Oct 2026 07:02:00 -0400

Entrada Therapeutics (Nasdaq: TRDA) announced that an independent Data Monitoring Committee (DMC) has recommended initiating Cohort 3 at a dose of 18 mg/kg in the company's ELEVATE-44-201 Phase 1/2 clinical study of ENTR-601-44, a treatment candidate for Duchenne muscular dystrophy (DMD).

The DMC reviewed safety and pharmacokinetic data from eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose portion of the study. The recommended 18 mg/kg dose for Cohort 3 represents an increase from 12 mg/kg in Cohort 2 and 6 mg/kg in Cohort 1.

ELEVATE-44-201 evaluates ENTR-601-44 in ambulatory participants aged four to 20 with DMD who

Entrada Therapeutics clears DMC review, advances DMD study to top dose

Wed, 14 Oct 2026 07:02:00 -0400

ELEVATE-44-201 evaluates ENTR-601-44 in ambulatory participants aged four to 20 with DMD who

Entrada Therapeutics reports early DMD drug trial safety data

Wed, 14 Oct 2026 07:00:17 -0400

Entrada Therapeutics (Nasdaq: TRDA) announced topline results from the first cohort of its Phase 1/2 ELEVATE-45-201 clinical study of ENTR-601-45, an investigational treatment for Duchenne muscular dystrophy (DMD) in patients amenable to exon 45 skipping.

Cohort 1 enrolled eight participants aged four to 20 who received three doses of ENTR-601-45 at 5 mg/kg or placebo. The study met its primary objectives of favorable safety and tolerability. The most common treatment-emergent adverse event was headache, reported in two participants. One participant experienced two serious adverse events — vomiting and pyrexia — which resolved. No study discontinuations occurred.

Secondary objectives showed a mean 0.10%

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

Wed, 14 Oct 2026 07:00:00 -0400

-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg --

-- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data --

-- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg --

-- Company expects a significant increase in dystrophin production and functional benefit in future cohorts while maintaining a convenient Q6W dosing schedule --

-- ELEVATE-45-201

Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45

Wed, 14 Oct 2026 07:00:00 -0400

-- Cohort 1 met the primary objectives of favorable safety and tolerability at the initial dose of 5 mg/kg --

-- ENTR-601-45 plasma exposures were consistent with those predicted based on juvenile non-human primate exposure data --

-- In line with expectations, the secondary objectives demonstrated a 0.10% mean increase in dystrophin production versus baseline in treated participants at the initial dose of 5 mg/kg --

-- Company expects a significant increase in dystrophin production and functional benefit in future cohorts while maintaining a convenient Q6W dosing schedule --

-- ELEVATE-45-201

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Wed, 14 Oct 2026 07:00:00 -0400

-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --

-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 --

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, an increase

Independent Safety Data Monitoring Committee Recommends Initiation of Cohort 3 at the Top Dose of 18 mg/kg in Entrada Therapeutics’ ELEVATE-44-201 Study

Wed, 14 Oct 2026 07:00:00 -0400

-- Company to receive ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 --

-- ELEVATE-44-201 Cohort 2 enrollment complete with data expected in Q1 2027 --

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that an independent Data Monitoring Committee (DMC), per study protocol, has reviewed all available safety and PK data from the eight participants enrolled in Cohort 2 of the double-blind, placebo-controlled, multiple ascending dose (MAD) portion of ELEVATE-44-201. The DMC recommended initiating Cohort 3 at the top dose of 18 mg/kg, an increase

Form SCHEDULE 13D/A Entrada Therapeutics, Filed by: MPM BioVentures 2014, L.P.

Thu, 10 Sep 2026 16:27:00 -0400
si-local-file:///var/storage/secattach/20260910/27048791.html

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

Thu, 10 Sep 2026 07:00:00 -0400

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community --

BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved. An Independent Grant Review Committee, consisting of neuromuscular specialists, patient advocates and health equity advocates, is

Entrada Therapeutics Announces Recipients of Fourth Annual DREAMS Grant Program

Thu, 10 Sep 2026 07:00:00 -0400

-- Announced following World Duchenne Awareness Day on September 7, grants are designed to support projects bridging healthcare disparities across the global Duchenne community --

BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the recipients of its 2026 DREAMS Grant Program: a competitive annual program that awards two $50,000 grants in support of projects working to better identify, understand and reach members of the Duchenne muscular dystrophy community who are currently underrepresented or underserved. An Independent Grant Review Committee, consisting of neuromuscular specialists, patient advocates and health equity advocates, is

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:30:00 -0400

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026. The options have an exercise price of $7.07 per share, which is equal to the closing price of the Company's common stock on August 31, 2026. The inducement grants were previously approved by the Compensation Committee of the Company’s Board

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wed, 02 Sep 2026 16:30:00 -0400

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced that the Company granted an aggregate of 61,365 restricted stock units (“RSUs”) and options to purchase 19,425 shares of the Company’s common stock to eight newly-hired non-executive employees under the Company’s 2025 Inducement Equity Plan (the “Inducement Plan”), effective as of September 1, 2026. The options have an exercise price of $7.07 per share, which is equal to the closing price of the Company's common stock on August 31, 2026. The inducement grants were previously approved by the Compensation Committee of the Company’s Board

Form 4 Entrada Therapeutics, For: Aug 24 Filed by: GADICKE ANSBERT

Wed, 26 Aug 2026 21:28:00 -0400
si-local-file:///var/storage/secattach/20260826/26983320.html

Form 4 Entrada Therapeutics, For: Aug 24 Filed by: GADICKE ANSBERT

Wed, 26 Aug 2026 21:28:00 -0400
si-local-file:///var/storage/secattach/20260826/26983320.html

Form 4 Entrada Therapeutics, For: Aug 24 Filed by: MPM BIOVENTURES 2018, L.P.

Wed, 26 Aug 2026 21:28:00 -0400
si-local-file:///var/storage/secattach/20260826/26983319.html

Form 4 Entrada Therapeutics, For: Aug 24 Filed by: MPM BIOVENTURES 2018, L.P.

Wed, 26 Aug 2026 21:28:00 -0400
si-local-file:///var/storage/secattach/20260826/26983319.html

Form SCHEDULE 13G/A Entrada Therapeutics, Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:23:00 -0400
si-local-file:///var/storage/secattach/20260814/26931001.html

Form SCHEDULE 13G/A Entrada Therapeutics, Filed by: TCG Crossover GP I, LLC

Fri, 14 Aug 2026 16:23:00 -0400
si-local-file:///var/storage/secattach/20260814/26931001.html

Form 4 Entrada Therapeutics, For: Aug 06 Filed by: PARMAR KUSH

Mon, 10 Aug 2026 19:55:00 -0400
si-local-file:///var/storage/secattach/20260810/26899625.html

Form 4 Entrada Therapeutics, For: Aug 06 Filed by: PARMAR KUSH

Mon, 10 Aug 2026 19:55:00 -0400
si-local-file:///var/storage/secattach/20260810/26899625.html

Form 4 Entrada Therapeutics, For: Aug 06 Filed by: ROCKLAGE SCOTT M

Mon, 10 Aug 2026 19:53:00 -0400
si-local-file:///var/storage/secattach/20260810/26899624.html

Form 4 Entrada Therapeutics, For: Aug 06 Filed by: ROCKLAGE SCOTT M

Mon, 10 Aug 2026 19:53:00 -0400
si-local-file:///var/storage/secattach/20260810/26899624.html

Form 144/A Entrada Therapeutics, Filed by: 5AM Ventures V, L.P.

Mon, 10 Aug 2026 19:50:00 -0400
si-local-file:///var/storage/secattach/20260810/26899620.html

Form 144/A Entrada Therapeutics, Filed by: 5AM Ventures V, L.P.

Mon, 10 Aug 2026 19:50:00 -0400
si-local-file:///var/storage/secattach/20260810/26899620.html